American Journal of Obstetrics & Gynecology
Volume 174, Issue 4 , Pages 1151-1160 , April 1996

Phase I/II study of PIXY321 in combination with cyclophosphamide and carboplatin in the treatment of ovarian cancer

Presented by invitation at the Fourteenth Annual Meeting of the American Gynecological and Obstetrical Society, Napa, California, September 7-9, 1995.

References 

  1. Perez RP, Hamilton TC, Ozols RF, Young RC. Mechanisms and modulation of resistance to chemotherapy in ovarian cancer. Cancer. 1993;71:1571–1580
  2. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N Engl J Med. 1992;327:28–35
  3. Speyer J, Mandeli J, Hochster H, et al.  A phase I trial of cyclophosphamide and carboplatinum with interleukin-3 in women with advanced stage ovarian cancer. Gynecol Oncol. 1995;56:387–394
  4. Ganser A, Lindemann A, Seipelt G, et al.  Clinical effects of recombinant human interleukin-3. Am J Clin Oncol. 1991;14:551–563
  5. Postmus PE, Gietema JA, Damsma O, et al.  Effects of recombinant human interleukin-3 in patients with relapsed small-cell lung cancer treated with chemotherapy: a dose finding study. J Clin Oncol. 1992;10:1131–1140
  6. Velduis GJ, Willemse PHB, vanGameren MM, et al.  Recombinant human interleukin-3 to dose-intensify carboplatin and cyclophosphamide chemotherapy in epithelial ovarian cancer: a phase I trial. J Clin Oncol. 1995;13:733–740
  7. Beisma B, Willemse PHB, Mulder NH, et al.  Effects of interleukin-3 after chemotherapy for advanced ovarian cancer. Blood. 1992;80:1141–1148
  8. Williams DE, Park LS. Hematopoietic effects of a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein. Cancer. 1991;67(suppl 10):2705–2707
  9. Smith HO, Goldberg GL, Carol L, et al.  Dose escalation combination carboplatin/cyclophosphamide for epithelial ovarian cancer. Eur J Gynaecol Oncol. 1994;6:411–417
  10. Rusthoven J, Levin L, Eisenhauer E, et al.  Two phase I studies of carboplatin dose escalation in chemotherapy-naive ovarian cancer patients supported with granulocyte-macrophage colony-stimulating factor. J Natl Cancer Inst. 1991;83:1748–1753
  11. Reyno LM, Egorin MJ, Canetta RM, et al.  Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer. J Clin Oncol. 1993;11:1156–1164
  12. Blessing JA. Design, analysis and interpretation of chemotherapy trials in gynecologic cancer. In:  Deppe G editors. Chemotherapy of gynecologic cancer. New York: Alan R Liss; 1984;p. 49–83
  13. Wilcoxon F. Individual comparisons by ranking methods. Biometrics. 1945;1:80–83
  14. Taylor C, Modiano M, Garrison L, et al.  PIXY plus carboplatin and adriamycin in patients with advanced gastrointestinal malignancy [Abstract]. Proc Am Soc Clin Oncol. 1993;12:195
  15. Raptis G, Gilewski T, Gabrilove J, et al.  Evaluation of PIXY321 as a myeloprotective agent in patients with metastatic breast cancer receiving doxorubicin and thiotepa [Abstract]. Proc Am Soc Clin Oncol. 1993;12:108
  16. Vadhan-Raj S, Papadoupoulos N, Burgess M, et al.  Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma. J Clin Oncol. 1994;12:715–724
  17. Curtis BM, Williams DE, Broxmeyer HE, et al.  Enhanced hematopoietic activity of a human granulocyte/macrophage colony stimulating factor - interleukin 3 fusion protein. Proc Natl Acad Sci U S A. 1991;88:5809–5813
  18. Bretti S, Kamthan A, Hicks F, et al.  Phase I study of sequential IL-3 and GM-CSF by continuous intravenous infusion [Abstract]. Proc Am Soc Clin Oncol. 1992;11:181
  19. Ganser A, Lindemann A, Ottman OG, Seipert G, Hess U, Geissler G. Sequential in vivo treatment with two recombinant human hematopoietic growth factors (interleukin-3 and granulocyte-macrophage colony stimulating factor) as a new therapeutic modality to stimulate hematopoiesis: results of a phase I study. Blood. 1992;79:2583–2591
  20. Brugger W, Frisch J, Schulz G, Pressler K, Mertelsmann R, Kanz L. Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following standard-dose combination chemotherapy with etoposide, ifosfamide, and cisplatin. J Clin Oncol. 1992;10:1452–1459
  21. O'Shaughnessy JA, Noone MH, Gossard M, et al.  Sequential interleukin-3 and granulocyte-macrophage colony stimulating factor is superior to either cytokine alone in ameliorating FLAC-induced myelosuppression. [Abstract] Proc Am Soc Clin Oncol. 1994;13:137
  22. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N Engl J Med. 1992;327:28–35
  23. Veldhius GJ, Willemse PHB, vanGameren MM, et al.  Recombinant human interleukin-3 to dose-intensify carboplatin and cyclophosphamide chemotherapy in epithelial ovarian cancer: a phase I trial. J Clin Oncol. 1995;13:733–740
  24. Williams DE, Park LS. Hematopoietic effects of a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein. Cancer. 1991;67(suppl 10):2705–2707
  25. Reyno LM, Egorin MJ, Canetta RM, et al.  Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer. J Clin Oncol. 1993;11:1156–1164
  26. McGuire WP, Hoskins WJ, Brady MF, et al.  Taxol and cisplatin improves outcome in advanced ovarian cancer as compared to cytoxan and cisplatin. Proc Am Soc Clin Oncol. 1995;771:
  27. McGuire WP, Hoskins WJ, Brady MS, et al.  A phase III trial of dose-intensive versus standard dose cisplatin and cytoxan in advanced ovarian cancer. Proc Int Gynecol Cancer Soc. 1991;3:35
  28. Kaye SB, Lewis CR, Paul J, et al.  Randomized study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet. 1992;340:329
  29. Alberts DS, Liu PY, Hannigan EV, et al.  Phase III study of intraperitoneal cisplatin/iv cyclophosphamide versus iv cisplatin/iv cyclophosphamide in patients with optimal disease stage III ovarian cancer: a SWOG-GOG-ECOG intergroup study (INT 0051). Proc Am Soc Clin Oncol. 1995;760

☆ From the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology,a and the Division of Oncology, Department of Medicine,b Albert Einstein College of Medicine, Bronx; the Department of Neoplastic Diseases, Mount Sinai Medical Center,c and the Division of Oncology, Department of Medicine, Kaplan Comprehensive Cancer Center, New York University Medical Center,d New York; and Immunex Corporation, Seattle.e

☆☆ Reprint requests: Carolyn D. Runowicz, MD, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, 1695 Eastchester Road, Suite 601, Bronx, NY 10461.

★ 0002-9378/96 $5.00 + 0 6/6/71412

PII: S0002-9378(96)70657-9

American Journal of Obstetrics & Gynecology
Volume 174, Issue 4 , Pages 1151-1160 , April 1996

Article Tools

* Image Usage & Resolution